
Alamos Gold Announces Results of the Annual General and Special Meeting of Shareholders and Changes to its Board of Directors
All amounts are in United States dollars, unless otherwise stated.
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) ('Alamos' or the 'Company') today reported a summary of the voting results of its Annual General and Special Meeting of Shareholders (the 'Meeting') held on May 29, 2025. The Company is also announcing the retirement of David Gower from the Board of Directors, and the appointment of Alexander Christopher, Chana Martineau, and Richard McCreary.
'On behalf of the Board and management team, I would like to extend our gratitude to David for his service to Alamos over the past 16 years. Since joining the Board of Directors in 2009, David's leadership and technical expertise have proven invaluable during a period of significant growth for Alamos. We wish him all the best in his future endeavours,' said John A. McCluskey, President and Chief Executive Officer. 'I would also like to welcome Alexander Christopher, Chana Martineau, and Richard McCreary as new board members. Alex, Chana and Rick complement our Board with tremendous technical, operational, capital markets, and financial expertise.'
Alexander Christopher has over 40 years of experience in the mineral exploration and mining industry, spending the majority of his career with Teck Resources Limited ('Teck') before retiring in 2024. Mr. Christopher held a number of management, commercial and technical positions in Teck's Exploration, Corporate Development and Project Groups. Mr. Christopher is a former director of Horizonte Minerals Plc, the Association of Mineral Exploration BC, and the Prospectors and Developers Association of Canada, where he served as President from 2021 to 2023. He is a member of the Engineers and Geoscientists British Columbia and possesses an Honours B.Sc. in Geology from McMaster University and an Environmental Biology Technology diploma from Canadore College.
Chana Martineau is the Chief Executive Officer of the Alberta Indigenous Opportunities Corporation ('AIOC'), a globally leading crown corporation dedicated to supporting Indigenous economic investment in large scale infrastructure through loan guarantees and capacity grant funding. Prior to leading the AIOC, Ms. Martineau was a vice president with Canadian Western Bank and spent more than a decade with Ernst & Young LLP. Currently she is a director of Cenovus Energy Inc. She is a recognized leader and speaker on Indigenous reconciliation. Ms. Martineau holds a degree in Economics from the University of Alberta and holds the ICD.D designation from the Institute of Corporate Directors. Ms. Martineau is a proud member of Frog Lake First Nation.
Richard McCreary has over 40 years of experience in the resource sector, both as a principal in executive and board roles with various companies, as well as a financial advisor in investment banking. Mr. McCreary started his career with Gulf Canada as an exploration geophysicist, later working with the Noranda-Falconbridge Group in engineering, technology development, and metals marketing; and later, as Senior Vice President, Corporate Development with Barrick. His most recent investment banking role was Deputy Chair Investment Banking at TD Securities, and prior to that, Head of CIBC's Global Mining Investment Banking Group. During his career, Mr. McCreary has acted as principal or lead financial advisor in some of the largest marquee transactions in the mining sector. Currently he is a director of ATEX Resources Inc. He holds an MBA in Finance and Strategy from McGill University, and a Master of Science and Bachelor of Science (Hons) in Geological Engineering from Queen's University.
Results of the Meeting
The Company is reporting the voting results of its Meeting held virtually on Thursday, May 29, 2025. The summary of the results are as follows:
1. Election of Directors
Each of the nominee directors listed in Alamos' management proxy circular dated April 9, 2025 was elected as a director as set forth in the table below:
2. Re-Appointment and Compensation of Auditors
KPMG LLP was appointed as the Company's auditor and the directors were authorized to fix the auditor's remuneration.
3. Long-Term Incentive Plan
The resolution approving the Company's Long-Term Incentive Plan was approved.
4. Employee Share Purchase Plan
The resolution approving the Company's Employee Share Purchase Plan was approved.
5. Amended and Restated Shareholder Rights Plan
The resolution approving the Company's Fifth Amended and Restated Shareholder Rights Plan was approved.
6. Approval of Approach to Executive Compensation
The non-binding advisory resolution approving the Company's approach to Executive Compensation was passed.
7. Shareholder proposal
The proposal seeking to amend By-Law No. 1 of the Company was denied as a resolution of the Company.
About Alamos
Alamos is a Canadian-based intermediate gold producer with diversified production from three operating mines in North America. This includes the Island Gold District and the Young-Davidson mine in northern Ontario, Canada, and the Mulatos District in Sonora State, Mexico. Additionally, the Company has a significant portfolio of development stage projects, including the Phase 3+ Expansion at Island Gold, and the Lynn Lake project in Manitoba, Canada. Alamos employs more than 2,400 people and is committed to the highest standards of sustainable development. The Company's shares are traded on the TSX and NYSE under the symbol 'AGI'.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Scott K. Parsons
Senior Vice President, Corporate Development & Investor Relations
(416) 368-9932 x 5439
Khalid Elhaj
Vice President, Business Development & Investor Relations
(416) 368-9932 x 5427
ir@alamosgold.com
Cautionary Note
The TSX and NYSE have not reviewed and do not accept responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge
Most of UnitedHealth Group's issues should be temporary. The two biggest threats to the healthcare giant are iffy. The price is right to buy UnitedHealth Group stock after its steep decline. 10 stocks we like better than UnitedHealth Group › UnitedHealth Group (NYSE: UNH) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months. A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. I have a different opinion, though. I think it's time to buy UnitedHealth Group stock. Here are three reasons why. I don't think investors should ignore UnitedHealth Group's issues. However, the challenges should be viewed with a long-term perspective. I suspect most of the problems the company faces should be temporary. UnitedHealth Group has already largely moved past the cyberattack that occurred in February 2024. Although it cost the healthcare company over $2 billion, that issue has already proven to be a short-lived one. Higher Medicare Advantage costs are the main culprit behind UnitedHealth Group's suspension of its 2025 full-year guidance. But the company says that it expects to return to growth in 2026. I believe this prediction because it makes sense. Insurers sometimes incur higher-than-anticipated costs and feel the pain for a while. However, once they adjust premiums, the problem goes away. UnitedHealth Group announced the sudden departure of former CEO Andrew Witty at the same time it withdrew its 2025 outlook. Any worries investors might have had surrounding this move probably dissipated quickly after they learned Stephen Hemsley was returning to run the company. Hemsley served as CEO from 2006 through 2017, a period when UnitedHealth Group stock more than tripled. I also view the two biggest threats to UnitedHealth Group as iffy. What are those threats? An alleged U.S. Department of Justice criminal investigation of the company and President Trump's stated goal to eliminate pharmacy benefits managers (PBMs). Noted that I used the word "alleged" to describe the U.S. Department of Justice probe. The Wall Street Journal reported on May 14, 2025, that "people familiar with the matter" revealed that the DOJ had launched a criminal investigation of UnitedHealth Group for possible Medicare fraud. However, the company quickly responded that it hadn't been notified of any DOJ investigation. That status hasn't changed. President Trump did announce that he wants to "cut out the middleman," a clear reference to PBMs. That's easier said than done, though, to put it mildly. Removing PBMs from the U.S. healthcare system would require a detailed, comprehensive plan that so far has not been provided. That plan would also have to pass in both the Senate and the House of Representatives. You can bet that the PBM industry, including UnitedHealth Group, would lobby fiercely against any such legislation. I think this threat, while serious, has a relatively low probability of actually materializing. Finally, I think all these issues are fully baked into UnitedHealth Group's share price. The stock currently trades at a forward price-to-earnings ratio of around 13.3. That's well below the S&P 500 healthcare sector forward earnings multiple of 16.6. It's also the lowest valuation for UnitedHealth Group in more than a decade. Could the stock fall further? Maybe, but I believe that UnitedHealth Group's share price has bottomed out. You might have noticed that UnitedHealth Group's share price has traded in a relatively narrow range since the steep decline in April and May. This trading pattern seems to confirm my view. Any good news for UnitedHealth Group could provide a nice catalyst. I predict that the company will have some positive developments in the not-too-distant future, potentially including new full-year guidance that calms investors. If I'm right, buying UnitedHealth Group stock now could pay off handsomely. Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 HSBC Holdings is an advertising partner of Motley Fool Money. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends HSBC Holdings and UnitedHealth Group. The Motley Fool has a disclosure policy. Opinion: It's Time to Buy UnitedHealth Group Stock After a 50% Plunge was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility
Netflix has a solid plan to become a trillion-dollar company by 2030. Veeva Systems still has a massive addressable market. 10 stocks we like better than Netflix › Broader equities have not performed particularly well in 2025. The S&P 500 is barely in the black year to date. However, considering it hovered near bear market territory a few weeks ago, things aren't so bad. Stocks might not be out of the woods, though. Economic issues could arise, sending markets down, as the Trump administration continues to implement its trade agenda. That said, regardless of what happens on that front, there are plenty of companies worth investing in. Here are two great examples: Netflix (NASDAQ: NFLX) and Veeva Systems (NYSE: VEEV). Netflix, a streaming specialist, has been grabbing headlines recently for all the right reasons. The stock is up for the year, financial results have been good, and management sees significant upside ahead. The company has plans to join the exclusive club of trillion-dollar stocks by 2030. From its current market cap of $522 billion, that will require a compound annual growth rate of 13.9%. That's nothing to sneeze at, but it's well within the company's reach, in my view. Five years ago, Netflix ended 2019 with $20.2 billion in revenue. Last year, that had risen to $39 billion -- a compound annual growth rate (CAGR) of 14.1%. True, a lot has changed since. There is more competition in the streaming field, for instance. Even so, Netflix has made changes that have kept it in the lead in the industry, including a crackdown on password sharing and the introduction of a low-priced ad-supported tier. The company doesn't grow its revenue quite as fast as it used to, but in the past five years, profits and free cash flow have soared. Meanwhile, there is still considerable room for growth in the streaming industry. Netflix's estimate of a $650 billion revenue opportunity reflects the fact that streaming still has yet to completely overtake entertainment. The industry's penetration should expand over the long run and benefit Netflix, considering its strong position, network effect, and brand name. Furthermore, it is increasingly using artificial intelligence (AI) to enhance its content strategy, which is already a key to its success. Though AI won't be the center of Netflix's universe, it can allow the company to make better movies for less money, something that will make a difference down the road. So the goal to achieve a trillion-dollar valuation in the next five years isn't just a pipe dream -- it is well within the company's powers. Even if it fails, though, the stock should deliver superior returns well beyond 2025. Veeva Systems isn't the biggest player in the cloud industry. That title arguably goes to Amazon, with other tech giants, such as Alphabet and Microsoft, not far behind. However, Veeva Systems is a leader in a niche within the industry. It offers cloud solutions primarily to life science companies such as drugmakers. The fact that the company's list of clients features some of the largest pharmaceutical players, including Merck, Novo Nordisk, and Eli Lilly, is telling. The company is doing something right. Here's what that thing is: It has developed a wealth of cloud services specifically catered to the stringent regulatory (and other) demands of the industry. Generic solutions won't do for many of these companies. Enter Veeva Systems. The cloud computing specialist's financial results also reflect its success. Revenue and earnings have been growing at a good clip. And when management set revenue goals to be achieved by a certain date in the past, Veeva has met the goal. It recently hit its $3 billion revenue run-rate target -- which, in 2019, it said it would achieve by the calendar year 2025. That's a management team investors can trust. Many CEOs overpromise and underdeliver. Meanwhile, Veeva still has plenty of white space ahead, with an estimated $20 billion addressable market. Revenue over the trailing-12-month period is $2.9 billion. Given the high switching costs, the company should remain a strong player in this niche for some time as it continues to make headway in its market. It could encounter some headwinds if the economy tanks, as it did a couple of years ago. But the company has recovered nicely since -- a microcosm of what its performance might look like over the long run. Even with occasional slowdowns, expect Veeva Systems to deliver above-average returns in the next decade. Before you buy stock in Netflix, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Netflix wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Amazon, Eli Lilly, and Novo Nordisk. The Motley Fool has positions in and recommends Alphabet, Amazon, Merck, Microsoft, Netflix, and Veeva Systems. The Motley Fool recommends Novo Nordisk and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. 2 Unstoppable Stocks to Consider Buying, Even Amid Market Volatility was originally published by The Motley Fool

Yahoo
20 minutes ago
- Yahoo
UBS identifies stock winners amid structural growth tailwinds
-- In a note to clients on Thursday, UBS analysts assessed "The Next Big Thing" in global equities, focusing on companies that leverage technology to disrupt various sectors. Through their "Global equity focus list," UBS anticipates "strong structural growth drivers to enable our recommendations to outperform the broader market". The investment theme highlights "greentech, enabling tech, fintech, and healthtech sectors," which UBS views as "leading disruptors in sectors undergoing technological transformation, which should lead to consequential and enduring impact". These stocks are collectively "expected to deliver superior earnings growth to the market, boosted by positive, durable structural trends supporting the theme". In enabling technology, UBS predicts significant growth, with the sector "projected to grow to USD 1.2 trillion by 2025, i.e., 15% CAGR from FY20-25". They "expect investors to benefit from increased tech spending and resulting strong revenue growth for the next few years," with Meta Platforms (NASDAQ:META), Alibaba (NYSE:BABA), Oracle Corporation (NYSE:ORCL), and Microsoft (NASDAQ:MSFT) among the names in its focus list. Greentech is supported by "long-term policy support as major economies work toward reducing carbon emissions and reaching net-zero targets." Rolls-Royce (OTC:RYCEY) is one of the names on the focus list. Fintech fundamentals "remain strong, supported by positive net interest income trends."UBS said Barclays was a top gainer in this area, while Euronext (EPA:ENX) NV is also on the list. While healthtech has seen challenges, UBS sees "significant catch-up potential, and generative A.I. progress should act as another catalyst," noting AstraZeneca (NASDAQ:AZN) as a top gainer. Alcon (NYSE:ALC) and Intuitive Surgical (NASDAQ:ISRG) are other healthtech names featured. Related articles UBS identifies stock winners amid structural growth tailwinds Activist investor Palliser Capital reportedly builds 5% stake in WH Smith Citi highlights sector opportunities based on recent flows